Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
Ionizing radiation emitter
DRUG CLASS:
Ionizing radiation emitter
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
177Lu-satetraxetan-lilotomab (4)
lutetium Lu 177 vipivotide tetraxetan (4)
ibritumomab tiuxetan (3)
177Lu-FAP-2286 (2)
radium Ra-223 dichloride (2)
CLR 131 (2)
lutetium Lu 177 dotatate (1)
PNT2002 (1)
1095 (0)
111In-DOTA-h11B6 (0)
177Lu HTK03170 (0)
177Lu-BiOncoFAP (0)
TLX250 (0)
177Lu-DTPA-SC16 (0)
177Lu-DTPA-omburtamab (0)
177Lu-EB-LM3 (0)
177Lu-LNC1004 (0)
177Lu-OncoFAP-23 (0)
177Lu-P17-087 (0)
177Lu-P17-088 (0)
177Lu-PSMA-EB-01 (0)
177Lu-PSMA-R2 (0)
177Lu-TE-1132 (0)
CYT 500 (0)
177Lu-rhPSMA-10.1 (0)
ITM-41 (0)
177LuFF-10158 (0)
BAY 3546828 (0)
3BP-3775 (0)
90Y-NM600 (0)
TLX66 (0)
AAA603 (0)
AT-001 (0)
Actinium-225 conjugated to daratumumab (0)
iodine-125 (0)
AvidinOx/Lu-177 DOTA biotin (0)
BAY 3563254 (0)
iodine I 131 tositumomab (0)
Boron-10 (0)
CAM-H2 (0)
CLDN18.2 targeted radiopharmaceutical therapeutic (0)
CTT1403 (0)
iodine I 131 derlotuximab (0)
samarium-153 DOTMP (0)
DARPin-conjugated radioligand therapeutic (0)
DR-18621-GBMF (0)
Debio 0228 (0)
Debio 1124 (0)
64Cu-Dotatate (0)
EBRGD (0)
EBTATE (0)
EGFR sdAb based radiotherapy (0)
iodine-125 (0)
FF21101 (0)
GPC3 targeted radiopharmaceutical therapy (0)
177Lu-DOTA-NNV003 (0)
IAB2MA RPT (0)
IAB56 (0)
IAB57 (0)
ITM-22 (0)
ITM-52 (0)
Lu 177 PSMA I&T (0)
RAD302 (0)
ITM-31 (0)
Lutetium-177 PNT6555 (0)
Lutetium-177-PEG-αvβ3-IAC (0)
epratuzumab Y-90 (0)
MVT-1075 (0)
166 holmium poliglusam (0)
NNV009 (0)
NNV013 (0)
iodine-125 (0)
PSMA targeted radiopharmaceutical therapeutic (0)
cesium-131 (0)
RAD204 (0)
RAD402 (0)
RAD502 (0)
RAD602 (0)
186Re (0)
Radspherin (0)
lutetium-177 DOTA satoreotide (0)
SSO111 (0)
67Cu MeCOSar octreotate (0)
177Lu-edotreotide (0)
palladium-103 (0)
Re (0)
Undisclosed cancer therapeutic (0)
Undisclosed next gen prostate cancer therapeutic (0)
Undisclosed radiopharmaceutical (0)
ZS04 (0)
actinium-225 radio-conjugate theranostic (0)
h5A10 (0)
yttrium Y-90 clivatuzumab tetraxetan (0)
huB7-H3 (0)
DK001 (0)
PNT2003 (0)
124I-8H9 (0)
radiolabelled olaratumab (0)
ATL101 (0)
sodium iodide I 131 (0)
177Lu-satetraxetan-lilotomab (4)
lutetium Lu 177 vipivotide tetraxetan (4)
ibritumomab tiuxetan (3)
177Lu-FAP-2286 (2)
radium Ra-223 dichloride (2)
CLR 131 (2)
lutetium Lu 177 dotatate (1)
PNT2002 (1)
1095 (0)
111In-DOTA-h11B6 (0)
177Lu HTK03170 (0)
177Lu-BiOncoFAP (0)
TLX250 (0)
177Lu-DTPA-SC16 (0)
177Lu-DTPA-omburtamab (0)
177Lu-EB-LM3 (0)
177Lu-LNC1004 (0)
177Lu-OncoFAP-23 (0)
177Lu-P17-087 (0)
177Lu-P17-088 (0)
177Lu-PSMA-EB-01 (0)
177Lu-PSMA-R2 (0)
177Lu-TE-1132 (0)
CYT 500 (0)
177Lu-rhPSMA-10.1 (0)
ITM-41 (0)
177LuFF-10158 (0)
BAY 3546828 (0)
3BP-3775 (0)
90Y-NM600 (0)
TLX66 (0)
AAA603 (0)
AT-001 (0)
Actinium-225 conjugated to daratumumab (0)
iodine-125 (0)
AvidinOx/Lu-177 DOTA biotin (0)
BAY 3563254 (0)
iodine I 131 tositumomab (0)
Boron-10 (0)
CAM-H2 (0)
CLDN18.2 targeted radiopharmaceutical therapeutic (0)
CTT1403 (0)
iodine I 131 derlotuximab (0)
samarium-153 DOTMP (0)
DARPin-conjugated radioligand therapeutic (0)
DR-18621-GBMF (0)
Debio 0228 (0)
Debio 1124 (0)
64Cu-Dotatate (0)
EBRGD (0)
EBTATE (0)
EGFR sdAb based radiotherapy (0)
iodine-125 (0)
FF21101 (0)
GPC3 targeted radiopharmaceutical therapy (0)
177Lu-DOTA-NNV003 (0)
IAB2MA RPT (0)
IAB56 (0)
IAB57 (0)
ITM-22 (0)
ITM-52 (0)
Lu 177 PSMA I&T (0)
RAD302 (0)
ITM-31 (0)
Lutetium-177 PNT6555 (0)
Lutetium-177-PEG-αvβ3-IAC (0)
epratuzumab Y-90 (0)
MVT-1075 (0)
166 holmium poliglusam (0)
NNV009 (0)
NNV013 (0)
iodine-125 (0)
PSMA targeted radiopharmaceutical therapeutic (0)
cesium-131 (0)
RAD204 (0)
RAD402 (0)
RAD502 (0)
RAD602 (0)
186Re (0)
Radspherin (0)
lutetium-177 DOTA satoreotide (0)
SSO111 (0)
67Cu MeCOSar octreotate (0)
177Lu-edotreotide (0)
palladium-103 (0)
Re (0)
Undisclosed cancer therapeutic (0)
Undisclosed next gen prostate cancer therapeutic (0)
Undisclosed radiopharmaceutical (0)
ZS04 (0)
actinium-225 radio-conjugate theranostic (0)
h5A10 (0)
yttrium Y-90 clivatuzumab tetraxetan (0)
huB7-H3 (0)
DK001 (0)
PNT2003 (0)
124I-8H9 (0)
radiolabelled olaratumab (0)
ATL101 (0)
sodium iodide I 131 (0)
›
Associations
(19)
News
Twitter
Trials
VERI cancer hierarchy
x
x
x
x
Reset Filters
CD20 positive
Follicular Lymphoma
CD20 positive
Follicular Lymphoma
rituximab + ibritumomab tiuxetan
Sensitive: A1 - Approval
rituximab + ibritumomab tiuxetan
Sensitive
:
A1
rituximab + ibritumomab tiuxetan
Sensitive: A1 - Approval
rituximab + ibritumomab tiuxetan
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
ibritumomab tiuxetan
Sensitive: A1 - Approval
ibritumomab tiuxetan
Sensitive
:
A1
ibritumomab tiuxetan
Sensitive: A1 - Approval
ibritumomab tiuxetan
Sensitive
:
A1
FOLH1 positive
Prostate Cancer
FOLH1 positive
Prostate Cancer
lutetium Lu 177 vipivotide tetraxetan
Sensitive: A1 - Approval
lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
A1
lutetium Lu 177 vipivotide tetraxetan
Sensitive: A1 - Approval
lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
A1
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
ibritumomab tiuxetan
Sensitive: A2 - Guideline
ibritumomab tiuxetan
Sensitive
:
A2
ibritumomab tiuxetan
Sensitive: A2 - Guideline
ibritumomab tiuxetan
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
CLR 131
Sensitive: B - Late Trials
CLR 131
Sensitive
:
B
CLR 131
Sensitive: B - Late Trials
CLR 131
Sensitive
:
B
No biomarker
Lymphoplasmacytic Lymphoma
No biomarker
Lymphoplasmacytic Lymphoma
CLR 131
Sensitive: B - Late Trials
CLR 131
Sensitive
:
B
CLR 131
Sensitive: B - Late Trials
CLR 131
Sensitive
:
B
SSTR positive
Neuroendocrine Tumor
SSTR positive
Neuroendocrine Tumor
lutetium Lu 177 dotatate
Sensitive: B - Late Trials
lutetium Lu 177 dotatate
Sensitive
:
B
lutetium Lu 177 dotatate
Sensitive: B - Late Trials
lutetium Lu 177 dotatate
Sensitive
:
B
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
lutetium Lu 177 vipivotide tetraxetan
Sensitive: B - Late Trials
lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
B
lutetium Lu 177 vipivotide tetraxetan
Sensitive: B - Late Trials
lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
B
FOLH1 expression
Prostate Cancer
FOLH1 expression
Prostate Cancer
PNT2002
Sensitive: B - Late Trials
PNT2002
Sensitive
:
B
PNT2002
Sensitive: B - Late Trials
PNT2002
Sensitive
:
B
FOLH1 expression
Prostate Cancer
FOLH1 expression
Prostate Cancer
pembrolizumab + lutetium Lu 177 vipivotide tetraxetan
Sensitive: C3 – Early Trials
pembrolizumab + lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
C3
pembrolizumab + lutetium Lu 177 vipivotide tetraxetan
Sensitive: C3 – Early Trials
pembrolizumab + lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
C3
TMPRSS2-ERG fusion
Prostate Cancer
TMPRSS2-ERG fusion
Prostate Cancer
radium Ra-223 dichloride
Resistant: C3 – Early Trials
radium Ra-223 dichloride
Resistant
:
C3
radium Ra-223 dichloride
Resistant: C3 – Early Trials
radium Ra-223 dichloride
Resistant
:
C3
RB deletion
Prostate Cancer
RB deletion
Prostate Cancer
radium Ra-223 dichloride
Resistant: C3 – Early Trials
radium Ra-223 dichloride
Resistant
:
C3
radium Ra-223 dichloride
Resistant: C3 – Early Trials
radium Ra-223 dichloride
Resistant
:
C3
ATM mutation
Prostate Cancer
ATM mutation
Prostate Cancer
enzalutamide capsule + lutetium Lu 177 vipivotide tetraxetan
Sensitive: C4 – Case Studies
enzalutamide capsule + lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
C4
enzalutamide capsule + lutetium Lu 177 vipivotide tetraxetan
Sensitive: C4 – Case Studies
enzalutamide capsule + lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
C4
FAP expression
Sarcoma
FAP expression
Sarcoma
177Lu-FAP-2286
Sensitive: D – Preclinical
177Lu-FAP-2286
Sensitive
:
D
177Lu-FAP-2286
Sensitive: D – Preclinical
177Lu-FAP-2286
Sensitive
:
D
FAP expression
Pancreatic Cancer
FAP expression
Pancreatic Cancer
177Lu-FAP-2286
Sensitive: D – Preclinical
177Lu-FAP-2286
Sensitive
:
D
177Lu-FAP-2286
Sensitive: D – Preclinical
177Lu-FAP-2286
Sensitive
:
D
ERBB3 expression
Renal Cell Carcinoma
ERBB3 expression
Renal Cell Carcinoma
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
ERBB3 expression
Prostate Cancer
ERBB3 expression
Prostate Cancer
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
ERBB3 expression
Colorectal Cancer
ERBB3 expression
Colorectal Cancer
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
ERBB3 expression
Ovarian Cancer
ERBB3 expression
Ovarian Cancer
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login